ONCAlert | Upfront Therapy for mRCC

Leukemias VIEW MORE >>

Although fludarabine, cyclophosphamide, and rituximab may be efficient in inducing remission for the treatment of patients with Binet A high-risk chronic lymphocytic leukemia, recent data published in Leukemia suggest there is no evidence that this would be better than the current standard of care, which is the “watch and wait” approach.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.